版本:
中国

BRIEF-Asit Biotech announces that it has achieved primary endpoint of phase I/IIa clinical trial with its hdm-ASIT+ product candidate for house dust mite rhinitis

April 4 Asit Biotech SA:

* Announces that it has achieved the primary endpoint of the phase I/IIa clinical trial with its hdm-ASIT+ product candidate for house dust mite rhinitis

* Confirmation of hdm-ASIT+'s safety and tolerability profile

* Conjunctival provocation test showed a slight numerical difference in favour of treated group compared to placebo group (not statistically significant) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐